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Abstract The bromodomain and extraterminal (BET) family member BRD4 is pivotal in the pathogenesis of cardiac hypertrophy. BRD4 induces hypertrophic gene expression by binding to the acetylated
chromatin, facilitating the phosphorylation of RNA polymerases II (Pol II) and leading to transcription
elongation. The present study identified a novel post-translational modification of BRD4: poly(ADPribosyl)ation (PARylation), that was mediated by poly(ADP-ribose)polymerase-1 (PARP1) in cardiac hypertrophy. BRD4 silencing or BET inhibitors JQ1 and MS417 prevented cardiac hypertrophic responses
induced by isoproterenol (ISO), whereas overexpression of BRD4 promoted cardiac hypertrophy,

Abbreviations: ANP, atrial natriuretic peptide; BET, bromodomain and extraterminal domain; BNP, brain natriuretic polypeptide; BW, body weight;
CDK9, cyclin-dependent kinase 9; co-IP, co-immunoprecipitation; EF, ejection fraction; FBS, fetal bovine serum; FS, fractional shortening; HATs, histone
acetyltransferases; HDACs, histone deacetylases; HE, hematoxylin-eosin; HW, heart weight; IF, immunofluorescence; ISO, isoproterenol; LVAW, left
ventricular anterior wall thickness; LVID, left ventricular internal diameter; LVPW, left ventricular posterior wall thickness; NC, negative control; NRCMs,
neonatal rat cardiomyocytes; NS, normal saline; PARP1, poly(ADP-ribose)polymerase-1; PBS, phosphate buffer solution; PSR, picrosirius red; RNA Pol II,
RNA polymerases II; SD, SpragueeDawley; siRNA, small-interfering RNA; TL, tibia length; TSS, transcription start sites; WGA, wheat germ agglutinin;
b-AR, b-adrenergic receptor; b-MHC, b-myosin heavy chain.
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confirming the critical role of BRD4 in pathological cardiac hypertrophy. PARP1 was activated in ISOinduced cardiac hypertrophy and facilitated the development of cardiac hypertrophy. BRD4 was involved
in the prohypertrophic effect of PARP1, as implied by the observations that BRD4 inhibition or silencing
reversed PARP1-induced hypertrophic responses, and that BRD4 overexpression suppressed the antihypertrophic effect of PARP1 inhibitors. Interactions of BRD4 and PARP1 were observed by coimmunoprecipitation and immunofluorescence. PARylation of BRD4 induced by PARP1 was investigated
by PARylation assays. In response to hypertrophic stimuli like ISO, PARylation level of BRD4 was
elevated, along with enhanced interactions between BRD4 and PARP1. By investigating the PARylation
of truncation mutants of BRD4, the C-terminal domain (CTD) was identified as the PARylation modification sites of BRD4. PARylation of BRD4 facilitated its binding to the transcription start sites (TSS) of
hypertrophic genes, resulting in enhanced phosphorylation of RNA Pol II and transcription activation of
hypertrophic genes. The present findings suggest that strategies targeting inhibition of PARP1-BRD4
might have therapeutic potential for pathological cardiac hypertrophy.
ª 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1.

Introduction

Pathological cardiac hypertrophy is an adaptive response to stress
stimulation or disease, which contributes to cardiac contractile
dysfunction and heart failure1e3. Its typical characteristics are
increased cardiomyocyte size, higher organization of sarcomere,
enhanced protein synthesis and reprogramming of fetal genes,
such as atrial natriuretic peptide (ANP), brain natriuretic peptide
(BNP), and b-myosin heavy chain (b-MHC)2. The regulatory
networks governing cardiac hypertrophy are under intense investigation. Epigenetic modifications are important contributors to
this process. Among them, histone acetylation is known to be
crucial in cardiac physiology and pathophysiology4e6, which involves three classes of regulators, including “writers” or histone
acetyltransferases (HATs), “erasers” or histone deacetylases
(HDACs) and “readers” or acetyl lysine binders7. Accumulating
evidences have revealed HDACs and HATs as positive and
negative regulators in pathological cardiac hypertrophy8e11.
Recently, the contribution of “readers” in cardiac hypertrophy
attracts mounting attention.
Bromodomain and extraterminal (BET) family proteins are
regarded as an important type of lysine acetylation “readers”. Since
their bromodomains are responsible for binding to acetylated lysine
residues in histones, they serve as chromatin-targeting modules that
decipher the histone acetylation code12e14. BET proteins have
attracted accumulating attentions for their participation in the
pathogenesis of cardiac diseases. The recent development of potent,
specific and reversible BET inhibitors, like the small molecule JQ1,
which competes and displaces bromodomains from acetylated
chromatin, has been implicated in suppressing innate inflammatory
and transcriptional networks in heart failure15e17. BET family
contains four subtypes, including BRD2, BRD3, BRD4 and BRDT,
among which, BRD4 has been shown as a nodal regulator of the
transcriptional program in cardiac hypertrophy18,19. Prohypertrophic stimuli facilitates the recruitment of BRD4 to the
promotor regions of target genes, and then induces the cyclindependent kinase 9 (CDK9)-mediated phosphorylation of RNA
polymerase II (RNA Pol II) at serine 2 (Ser2), finally leading to
increased transcriptional elongation of hypertrophic genes19,20.
Interestingly, studies in our laboratory demonstrated an interaction between BRD4 and poly(ADP-ribose) polymerase 1

(PARP1) in cardiac hypertrophy, as implied by the coimmunoprecipitation (co-IP) and immunofluorescence (IF) results. PARP1, a member of PARP enzyme family, can modulate
diverse biological processes through covalent transfer of ADPribose from NADþ onto substrate proteins or DNA chain, known
as poly(ADP-ribosyl)ation (PARylation)21e23. Our previous
studies have revealed that PARP1 is activated and PARylates
FOXO3, STAT3 and HMGB1 in cardiac hypertrophy, whereas
inhibition of PARP1 by 3-aminobenzamide (3AB) and veliparib
(ABT-888) prevents the development of cardiac hypertrophy24e27.
The observations of BRD4/PARP1 interaction thus prompt our
hypothesis that BRD4 might act as a substrate protein of PARP1,
and that PARylation of BRD4 by PARP1 might facilitate the
recruitment of BRD4 to hyper-acetylated chromatin and enhance
RNA Pol II phosphorylation, ultimately promoting transcription
activation of hypertrophic biomarkers. The present study
attempted to provide mechanistic insights into the interaction of
BRD4 and PARP1 in pathological cardiac hypertrophy.
2.
2.1.

Materials and methods
Primary culture of neonatal rat cardiomyocytes (NRCMS)

Primary culture of NRCMs, isolated from the hearts of
SpragueeDawley (SD) rats (1- to 3-day-old) obtained from the
Experimental Animal Center of Sun Yat-sen University, was
performed as described previously28. NRCMs were isolated and
seeded onto six well plates at a density of 1  106 cells and
cultured in DEME (Gibco, BRL Co., Ltd., USA) supplemented
with 10% fetal bovine serum (FBS) and 0.1 mmol/L
5-bromodeocyuridine at 37  C with 5% CO2. Finally, ISO
(SigmaeAldrich, St. Louis, MO, USA) was added to medium at a
concentration of 10 mmol/L and the cells were further incubated
for indicated time.
2.2. Animal model, echocardiography and morphometric
measurements
The animal experiments were approved by the Research Ethics
Committee of Sun Yat-sen University, and were conducted under
the Guide for the Care and Use of Laboratory Animals (NIH
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Publications No. 8023, revised 1978). SD rats (male, 180e220 g,
SPF grade, certification Nos. 44007200054721 and
1100112011043685) from the Experimental Animal Center
of Guangzhou University of Chinese Medicine (Guangzhou,
China) and Charles River (Beijing, China), respectively,
were housed under controlled environmental conditions (a
12-h:12-h light/dark cycle and a room temperature of 21e23  C)
and had free access to standard laboratory food and water. ISO
(1.2 mg/kg/day) was subcutaneously (s.c.) injected for seven
consecutive days to induce cardiac hypertrophy. The vehicle
control group was given equal treatments of normal saline (NS).
Two-dimensional guide M-mode echocardiography was conducted with a Technos MPX ultrasound system (ESAOTE,
SpAESAOTE SppA, Italy)29. After that, the rats were sacrificed
and then their hearts were quickly removed, weighed and then
used for other measurements.
2.3.

Intramyocardial delivery of adeno-associated virus

SD rats were randomized divided into two groups and anaesthetized with sodium pentobarbital (30 mg/kg, i.p.). Fentanyl
(0.16 mg/kg, s.c.) was given as an analgesic agent and then rats
were endotracheally intubated noninvasively connecting to respiratory machine. Open thoraces at the left fourth intercostal space
to expose the heart. Then 200 mL of adeno-associated virus (1012
particles) were injected into five to six sites along the left ventricular walls directly by a curved 25-gauge needle21. After the
operation, thoraces and incision were sutured, and gentamicin was
given to prevent infection. Adeno-associated virus expressing the
si-RNA sequence of BRD4 (AAV-si-BRD4) was constructed by
Hanbio Biotechnology (Shanghai, China).
2.4.

Morphological and histology analysis

Hearts from animals were excised, washed in 10% potassium
chloride solution and fixed with 4% paraformaldehyde. Then the
hearts were embedded in paraffin and cut transversely into 5 mm
sections. Serial sections were stained with hematoxylin-eosin
(HE) or wheat germ agglutinin (WGA) staining to measure
myocyte cross sectional areas and Picrosirius red (PSR) staining to
detect collagen content.
2.5. Western blot assay and co-immunoprecipitation (co-IP)
analysis
Western blot assays were performed as previously reported30. For
Western blotting, primary antibodies against BRD4 (Cat#128874;
rabbit, diluted 1:1000), PARP1 (Cat#9532S; rabbit, diluted
1:1000), RNA Pol II (Cat#2629; mouse, diluted 1:1000) was
purchased from Cell signaling Technology. RNA Pol II phosphorylation on serine 2 (Cat# ab193468; rabbit, diluted 1:5000)
was bought from Abcam, ANP (Cat# PAA225Ra02; rabbit,
diluted 1:1000) was purchased from Cloud-Clone Corp., PAR
(Cat#: 4335-MC-100-AC; mouse, diluted 1:1000) was purchased
from Trevigen (Gaithersburg, MD, USA). The signals of protein
level were visualized by Image Quant LAS 4000 mini produced
by GE healthcare (Waukesha, WI, USA). The intensities of the
blots were quantified by the Quantity One (Bio-Rad) software.
a-Tubulin was used as an internal control for total proteins.
For co-IP, anti-BRD4 (rabbit diluted 1:100) antibody and antiPARP1 (rabbit, diluted 1:10) antibody. The IP lysates (400 mg)
were incubated with the corresponding primary antibodies

overnight (rabbit normal IgG was served as control), and were
incubated with protein G-agarose beads (Pierce, Rockford, IL,
USA) at 4  C for 4 h. The immunoprecipitated proteins were
observed by Western blot analysis.
2.6. Quantitative real-time polymerase chain reaction (qRTPCR)
Total RNA from heart tissues or cultured cells was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA, USA). The RNA extract
was reversely transcribed to cDNA by the One-step RT Kit
(Thermo Fisher Scientific, USA). The mRNA levels of each targeted genes were determined by using SYBR-Green Quantitative
PCR kit (TOYOBO, Japan) in iCycler iQ system (Bio-Rad, USA).
The amplification conditions were as follow: 15 min at 95  C,
followed by 40 cycles of 30 s at 95  C, 1 min at 55  C and 30 s at
72  C. All PCR assays were done in triplicate. Rat-specific primers
were synthesized by Sangon (Shanghai, China; Supporting Information Table S1). b-Actin was used as an endogenous control.
2.7.

RNA interference, plasmid transfection

Three different duplex siRNAs for BRD4 (si-01, si-02, and si-03),
PARP1 and negative control (NC) siRNA were purchased from
GenePharma (Shanghai, China). The sequences were listed in
Supporting Information Table S2. RNA interference was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Western blot
was conducted to determine the silencing efficiency. Given that
the target effect of the siRNAs, endogenous BRD4 was knocked
down using the si-421 (Supporting Information Fig. S1).
The BRD4 and Flag-PARP1 plasmids were bought from
Genechem (Shanghai, China). Three large deletion BRD4 mutants
(P1, P2 and P3) were constructed by inserting into the eukaryotic
expressing vector GV219 with HA-tag (P1, 1e500 amino acids;
P2, 501e699 amino acids; P3, 700e1400 amino acids). Cardiomyocytes were transfected with the plasmids. After treatment
for 48 h, the cells were stimulated with or without ISO for 12 h.
2.8.

ChIP qPCR

Chromatin was crosslinked in 1% formaldehyde for 10 min. The
cross-linking reaction was stopped with glycine for 5 min. Then
the cells were washed with ice cold paraformaldehyde in phosphate (PBS), harvested in PBS with protease and phosphatase
inhibitors, frozen in liquid nitrogen and stored at 80  C until
processed. NRCMs were resuspended in Farnham lysis buffer
(5 mmol/L PIPES, 85 mmol/L KCl, 0.5% NP40, Roche protease
inhibitor cocktail) with phosphatase inhibitors and then centrifugated at 2000 rpm for 5 min at 4  C. After centrifugation,
pellets were resuspended in RIPA buffer (1PBS, 1% NP40, 0.5%
sodium deoxycholate, 0.1% SDS, Roche protease inhibitor cocktail) with protease inhibitors and transferred to microfuge tubes
for sonication by a Sonics VibraCell sonicator (Covaris, USA).
After sonication, sheared chromatin was collected in supernatant
by centrifugation at 14,000 rpm for 15 min at 4  C. Cleared
chromatin was then immunoprecipitated with 5 mg of antibody
BRD4 (Bethyl, A301-985A) attached to protein G Dynabeads
(Invitrogen, USA). Following overnight IP, beads were washed
five times and DNA was eluted in TE buffer (10 mmol/L Tris HCl,
0.1 mmol/L Na2EDTA) at 65  C for 15 min. Following reversal of
crosslinks, RNase and proteinase treatment, DNA was purified
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using the PCR Purification Kit (Thermo Fisher Scientific, Rockford, IL, USA) according to the protocol and used for qPCR
investigation. Rat-specific primers were synthesized by Sangon
(Supporting Information Table S3).
2.9.

Measurement of cell surface area

NRCMs grown in 48-well plates were fixed with 4% paraformaldehyde in PBS for 15 min at room temperature, and further
incubated with 0.3% TritonX-100 for 10 min, and then incubated
with 0.1% rhodamine-phalloidin (Invitrogen, Carlsbad, CA, USA)
for 1 h. After washing with PBS, the cells were incubated with
DAPI (Cell Signaling Technology, USA). The cell surface area
from randomly selected field fields (50 for each group) was
measured using the built-in image analysis software.
2.10.

Immunofluorescence (IF) assay

NRCMs seeded on coverslips were fixed with 4% paraformaldehyde for 30 min. After washing with PBS for three times,
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the cells were permeabilized with 0.3% Triton X-100 for 10 min
and followed by incubation with blocking solution at room temperature for 1 h. The cells were further treated with primary antibodies against BRD4 (diluted 1:50), and PARP1 (diluted 1:50)
overnight at 4  C, and then incubated with Alexa Fluor-labeled
secondary antibody (diluted 1:100, Proteintech Group, USA). The
coverslips were mounted with DAPI were detected by a confocal
microscope (Zeiss, Germany).

2.11.

Data and statistical analysis

The data and statistical analysis in this study comply with the
recommendations on experimental design and analysis in pharmacology31. The data were presented as mean  standard error of
mean (SEM). Statistical analyses between two groups were performed by unpaired Student’s t-test. Differences among multiple
groups were tested by one-way ANOVA with Bonferroni post hoc
test. In all cases, differences were considered statistically significant with P < 0.05.

Figure 1 BRD4 expression was upregulated in hypertrophic NRCMs following ISO treatment. Cultured NRCMs were incubated with 10 mmol/L
ISO for the indicated durations. (A) The mRNA levels of Anp, Bnp were determined by qRT-PCR. (B) The protein expression of ANP was detected by
Western blot analysis. (C) Cells were treated with 10 mmol/L ISO for 12 h. The cell surface area was measured by rhodamine-phalloidin staining. Scale
bar Z 20 mm. (D) Brd4 mRNA expression was determined by qRT-PCR. (E) and (F) Western blot analysis was conducted to detect the protein level of
BRD4, total RNA Pol II and phosphorylated RNA Pol II. (G) The total expression PARP1 and PARP1 activity were determined by Western blot. Data
are presented as mean  SEM, n Z 4; *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control group.
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3.

Results

3.1. BRD4 expression and PARP1 activity were increased in
ISO-induced cardiac hypertrophy in vitro and in vivo
ISO, a nonselective b-adrenergic receptor (b-AR) agonist, has
been widely used to induce cardiac hypertrophy24,32. NRCMs
were incubated with 10 mmol/L ISO for the times indicated. As
showed in Fig. 1A and B, ISO treatment for 6 and 12 h significantly elevated the expression of ANP and BNP, which are the
markers of cardiac hypertrophy. Cell surface area was increased
after stimulation by ISO for 12 h (Fig. 1C). These results indicate
that ISO-induced cardiomyocyte hypertrophy model was successfully established. In these hypertrophic cardiomyocytes, the
mRNA levels of Brd2 and Brd4 were increased while Brd3 was
not significantly changed (Fig. 1D and Supporting Information
Fig. S2). Furthermore, ISO induced elevation of BRD4 protein
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expression (Fig. 1E). Since gene transcription elongation induced
by BRD4 is dependent on the phosphorylation of RNA Pol II, we
detected the changes of phosphorylated RNA Pol II in hypertrophic cardiomyocytes. Western blot analysis suggested that Pol II
phosphorylation was prominently increased by ISO treatment for
6 and 12 h, although the total protein expression was unaltered
(Fig. 1F). The activity of PARP1, as determined by the PARylation
level of total proteins, was elevated by ISO treatment without
affecting PARP1 protein expression (Fig. 1G).
In vivo, SD rats were submitted to subcutaneous injection of
ISO (1.2 mg/kg/day, for 7 days) to stimulate pathological cardiac
hypertrophy. In this study, the hearts of ISO-treated rats were
obviously larger than those of control animals receiving NS, and
revealed typical hypertrophic changes, as showed by gross
morphologic examination, HE staining, PSR staining and echocardiographic analysis (Fig. 2AeD). ISO triggered a tendency for
increases in left ventricular anterior wall thickness (LVAW), left

Figure 2 BRD4 expression was upregulated in hypertrophic hearts of SD rats induced by ISO treatment. SD rats were submitted to the s.c.
injection of ISO (1.2 mg/kg/day) for 7 days. The control animals obtained normal saline (NS). (A)e(D) Gross hearts, HE-stained and PSR-stained
cross sections of the left ventricle, and representative echocardiographic graphs are shown, respectively. Scale bar Z 2 mm (A), 50 mm (B) and
(C). (E) The ratios of HW/BW and HW/TL were measured. (F) and (H) The mRNA levels of Anp, Bnp and Brd4 were detected by qRT-PCR. (G)
and (I) The protein levels of ANP, BNP and BRD4 were determined by Western blot in cardiac tissues. (J) and (K) Western blot analysis was
conducted to determine the phosphorylation of RNA Pol II, total expression and activity of PARP1. Data are presented as the mean  SEM,
n Z 6; *P < 0.05, **P < 0.01, ***P < 0.001 vs. NS group.
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ventricular posterior wall thickness (LVPW), ejection fraction (EF
%) and fractional shortening (FS%), as well as a tendency for
reduced left ventricular internal diameter (LVID) (Supporting
Information Table S4). The ratios of heart weight (HW)/body
weight (BW) and heart weight/tibia length (TL) were also
increased in ISO group (Fig. 2E). In addition, the mRNA and
protein levels of hypertrophic markers, including ANP and BNP,
were remarkably elevated (Fig. 2F and G). The above results
suggest the successful induction of cardiac hypertrophy in SD rats
by ISO. In the cardiac tissues of these cardiac hypertrophic rats,
both mRNA and protein expressions of BRD4 were significantly
upregulated (Fig. 2H and I), accompanied with an increased
phosphorylation level of RNA Pol II (Fig. 2J). Additionally, the
activity of PARP1 was markedly enhanced following ISO treatment (Fig. 2K). Consistent with the in vitro observations, these
in vivo results confirm that BRD4 expression and PARP1 activity
are increased in cardiac hypertrophy.
3.2. BRD4 inhibition repressed cardiac hypertrophy in vitro and
in vivo

BRD4 by siRNA remarkably attenuated ISO-induced hypertrophic
responses, as demonstrated by the expressions of ANP and BNP,
as well as the cardiomyocyte surface area (Fig. 3CeE). In the
contrary, overexpression of BRD4 by transfection with plasmid
encoding BRD4 augmented the cell surface area and expressions
of hypertrophic genes (Fig. 4AeC), together with an increased
phosphorylation of RNA Pol II (Fig. 4D).
Moreover, AAV-si-BRD4 was introduced into the left ventricles
of SD rats through intramyocardial injection. The delivery of AAVsi-BRD4 attenuated ISO-induced hypertrophic response in vivo, as
demonstrated by gross morphologic examination, HE staining,
PSR staining, WGA staining, echocardiography data, the HW/BW
and HW/TL ratios, as well as the expression of hypertrophic
marker genes (Fig. 5 and Supporting Information Table S5).
Furthermore, the expression of BRD4 is associated with the degree
of cardiac hypertrophy (Supporting Information Fig. S3). Taken
together, these observations suggest that BRD4 overexpression
could promote cardiac hypertrophy, whereas BRD4 knockdown or
inhibition ameliorates pathological cardiac hypertrophy.
3.3.

Since the above findings revealed an upregulation of BRD4 in
cardiac hypertrophy, it is hypothesized that inhibition of BRD4
might protect against cardiac hypertrophy. To test the hypothesis,
BET inhibitors JQ1 and MS417 were used to treat cardiomyocytes
(1 mmol/L for 6 h)33e35. As shown in Fig. 3A and B, both JQ1 and
MS417 inhibited ISO-induced elevation of mRNA and protein
levels of ANP and BNP. Similarly, knockdown of endogenous
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PARP1 accelerated cardiac hypertrophy

To investigate the involvement of PARP1 in cardiac hypertrophy,
PARP1 was inhibited or overexpressed in NRCMs. PARP1 inhibitors 3AB and ABT-888 (10 mmol/L for 24 h) significantly
reversed ISO-induced ANP upregulation (Fig. 6A). By contrast,
infection of Ad-PARP1 enhanced the protein expression of ANP
(Fig. 6B). We also examined the role of PARP1 in cardiac

Figure 3 BRD4 inhibitors JQ1 and MS417 or BRD4 knockdown attenuated hypertrophic responses in cardiomyocytes treated with ISO. Cells
were treated with BET inhibitors JQ1 and MS417, siRNA targeting Brd4 (si-BRD4) or negative control (NC) for 48 h, and further incubated with
or without 10 mmol/L ISO for 12 h. (A)e(D) The mRNA and protein levels of ANP, BNP, BRD4 were detected by qRT-PCR and Western blot. (E)
The cell surface area was measured by rhodamine-phalloidin staining. Scale bar Z 20 mm. Data are presented as the mean  SEM, n Z 4;
*P < 0.05, **P < 0.01, ***P < 0.001 vs. Con or NC group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. ISO or NCþISO group.
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Figure 4 BRD4 overexpression led to hypertrophic responses in NRCMs. Cells were transfected with GV219-BRD4 plasmid or blank vector.
(A) The cell surface area was measured by rhodamine-phalloidin staining. Scale bar Z 20 mm. (B) The mRNA levels of Anp and Bnp were
detected by qRT-PCR. (C) BRD4 and ANP protein level was detected by Western blot. (D) The phosphorylation of RNA Pol II was determined by
Western blot analysis. Data are presented as the mean  SEM, n Z 4; *P < 0.05, **P < 0.01, ***P < 0.001 vs. Vector group.

hypertrophy in vivo. 3AB was treated in rats (20 mg/kg/day, i.p.) 7
days before ISO injection and continuing for 7 days. As shown in
Supporting Information Fig. S4, 3AB ameliorated ISO-induced
cardiac hypertrophy in vivo. Our results thus confirm that
PARP1 accelerated cardiac hypertrophy.
3.4.

PARP1 interacted with BRD4 and PARylated BRD4

The colocalization of BRD4 and PARP1 in NRCMs was observed
by confocal microscopy (Fig. 7A). As implied by the co-IP data,
PARP1 was detected in precipitations pulled down by BRD4
antibody (Fig. 7B), while BRD4 was detected in proteins
precipitated by anti-PARP1 consistently (Fig. 7C). These findings
provide solid evidence of the interaction between BRD4 and
PARP1 in cardiomyocytes. Since the function of PARP1 is mainly
dependent on its PARylated activity, we further sought to determine whether BRD4 is PARylated by PARP1 in NRCMs. The
PARylation assay results demonstrate that PARylation level of
BRD4 was elevated by Ad-PARP1 infection, but was eliminated in

the presence of PARP1 inhibitors 3AB and ABT-888 (Fig. 7D).
Moreover, PARP1-mediated PARylation of BRD4 was restrained
by transfection with si-PARP1 (Fig. 7E). These observations thus
suggest that BRD4 may serve as a substrate of PARP1, and that
PARylation of BRD4 is dependent on the activity of PARP1. In
ISO-treated cardiomyocytes, interaction between PARP1 and
BRD4 was enhanced, accompanied with the increase of BRD4
PARylation (Fig. 7F). Furthermore, PARP1-mediated PARylation
of BRD4 was also detected in rat heart tissues. The results show
that BRD4 PARylation was increased by ISO treatment but was
alleviated by 3AB treatment (Fig. 7G), confirming that BRD4 is
PARylated by PARP1 in vivo. To further identify the potential
PARylated sites of BRD4 by PARP1, we constructed three truncation mutants of BRD4 with HA tag: P1 (1e500 amino acids), P2
(501e699 amino acids) and P3 (700e1400 amino acids), and
performed IP assays to test the PARylation levels of these mutants.
The results show that only P3 was PARylated, suggesting that the
PARylation reside of BRD4 is within 700e1400 amino acids,
where contains the CTD domain (Fig. 7H). Taken in conjunction,
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Figure 5 BRD4 knockdown protected SD rats from ISO-induced cardiac hypertrophy. SD rats received intramyocardial injections of adenoassociated virus encoding si-BRD4 (AAV-si-BRD4, 1012 particles), the control animals received si-NC (AAV-si-NC, 1012 particles), followed by
isoprenaline injection (1.2 mg/kg/day, s.c., 7 days) or an equal volume of normal saline (NS). (A)e(E) Hypertrophic changes of the hearts were
observed by gross morphologic examination (A), HE staining (B), PSR staining (C), WGA staining (D) and echocardiography (E and Table S4).
Scale bar Z 50 mm (BeD). (F) and (G) The HW/BW and HW/TL ratios were calculated. (H) and (I) The mRNA and protein levels of ANP, BNP
and BRD4 were measured by qRT-PCR and Western blot. Data are presented as the mean  SEM, n Z 7; *P < 0.05, **P < 0.01, ***P < 0.001
vs. NS group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. NSþISO group.

Figure 6 The involvement of PARP1 in cardiac hypertrophy. (A) Cells were incubated with 3AB or ABT888 (10 mmol/L, 24 h) followed by
incubation with ISO (10 mmol/L, 12 h). The protein level of ANP were determined by Western blot. (B) Cells were infected with PARP1
adenovirus. Western blot analysis was conducted to determine the change of ANP expression. All values are presented as the mean  SEM,
n Z 4; *P < 0.05, **P < 0.01, ***P < 0.001 vs. Con or Ad-GFP group; #P < 0.05, ##P < 0.01 vs. ISO group.
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Figure 7 PARP1 interacts and poly(ADP-ribosyl)ates BRD4. (A) The intracellular colocalization of PARP1 and BRD4 was confirmed in
NRCMs, by confocal microscopy. (B) NRCMs were transfected with infected with GV219-BRD4 plasmid and were precipitated by anti-BRD4,
followed by subjection to co-IP assays. (C) NRCMs were infected with Ad-PARP1 and were precipitated by anti-PARP1 for BRD4 detection in
reciprocal co-IP assays. (D) NRCMs were incubated with 3AB or veliparib (ABT-888) followed by Ad-PARP1 infection, immunoprecipitated
with anti-BRD4 and subsequently subjected to immunoblotting assays. (E) NRCMs were transfected with si-PARP1 and then immunoprecipitated
with anti-BRD4 and subsequently subjected to immunoblotting assays. (F) NRCMs were incubated with ISO and then immunoprecipitated with
anti-BRD4 and subsequently subjected to immunoblotting assays. (G) Rat heart tissues, which were treated with 3AB followed by ISO, were
immunoprecipitated with anti-BRD4 and subsequently subjected to Western blot analysis. (H) Three large deletion BRD4 mutants (P1, P2 and P3)
were detected by immunoprecipitation assays. P1: 1e500 amino acids; P2: 501e699 amino acids; P3: 700e1400 amino acids. Data are presented
as the mean  SEM, n Z 3; *P < 0.05, **P < 0.01 vs. Control group; #P < 0.05, ##P < 0.01 vs. Ad-PARP1 group.

these observations indicate that PARP1 interacts with BRD4 and
PARylates it at the CTD domain.

3.6. The transcription elongation mediated by BRD4 is
promoted by PARP1

3.5. Involvement of BRD4 in PARP1-mediated cardiomyocyte
hypertrophy

BRD4 has previously been shown to be recruited to the TSS of
hypertrophic genes36,37. In our study, we verified the binding of
BRD4 on ANP and BNP TSS through ChIP-qPCR and used bactin as a negative control to demonstrate the specificity of BRD4
binding to ANP and BNP promotors (Supporting Information
Fig. S5). Based on the above findings, it is hypothesized whether
or not this process is affected by PARP1. To test this hypothesis,
cultured NRCMs were infected with Ad-PARP1 or treated with
ABT-888 after ISO stimulation, followed by ChIP experiments to
test the binding capacity of BRD4 to TSS of ANP and BNP
(Fig. 9A). As shown in Fig. 9B and C, ISO treatment induced the
recruitment of BRD4 at the TSS of ANP and BNP, whereas

Since BRD4 acts as a downstream substrate of PARP1, we further
explored whether PARylation of BRD4 is involved in the prohypertrophic effects of PARP1. As shown in Fig. 8A and B, inhibition of BRD4 by JQ1 or MS417, or knockdown of BRD4 by
siRNA remarkably repressed Ad-PARP1-mediated upregulation of
ANP. In the contrary, overexpression of BRD4 abolished the antihypertrophic effect of PARP1 inhibitors (Fig. 8C). These rescue
experiments support the conclusion that BRD4 is involved in the
PARP1-induced cardiac hypertrophy.

PARylation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy

1295

Figure 8 Involvement of BRD4 in PARP1-mediated cardiomyocyte hypertrophy. (A) NRCMs were incubated with 3AB or ABT888
(10 mmol/L, 24 h) followed by Ad-PARP1 infection. The protein level of ANP was determined by Western blot. (B) Cells were transfected with siBRD4 followed by infected with PARP1 adenovirus. (C) Cells were incubated with ABT888 (10 mmol/L, 24 h) followed by ISO treatment and
then transfected with BRD4 plasmid. Western blot analysis was conducted to determine the change of ANP expression. All values are presented as
the mean  SEM, n Z 4; *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. Ad-PARP1 or ISO
group; $$P < 0.01 vs. ISOþABT888 group.

PRAP1 inhibitor ABT-888 reversed the effect of ISO. In addition,
PARP1 overexpression promoted the binding of BRD4 to the TSS
of hypertrophic biomarkers (Fig. 9D and E). Moreover, overexpression of PARP1 enhanced the phosphorylation of RNA Pol
II, which was inhibited by BRD4 inhibitors JQ1 and MS417
(Fig. 9F). Taken together, these data imply that PARylation of
BRD4 by PARP1 might facilitate the binding of BRD4 to the TSS
of hypertrophic genes, enhancing the phosphorylation of RNA Pol
II, subsequently promoting the transcription of hypertrophic genes
and leading to cardiac hypertrophy.

4.

Discussion

During pathological cardiac hypertrophy, ANP and BNP, small
peptide hormones encoded by the Nppa and Nppb genes and are
some of the most commonly measured members of the fetal gene
program38, are secreted in response to cardiac wall pressure.
Therefore, they are regarded as typical biomarkers of cardiac
hypertrophy and heart failure38,39.

Epigenetic readers have attracted increasing attention
following the discovery that they are pivotal in the pathogenesis of
numerous diseases. Being one of the most attractive epigenetic
readers, the BET family is capable to bind to the acetyl-lysine
residues in histones, thus regulating transcription program36,37.
Evidences indicated that inhibitors of BET family protect against
cardiac diseases such as heart failure, cardiac hypertrophy and
acute myocardial infarction, suggest the potential of BET family
proteins as promising therapeutic targets16,40e42. Among all these
BET family proteins, BRD4 has been shown to be involved in
pathological cardiac hypertrophy19,20,43. In line with these findings, the present study confirms that BRD4 plays a crucial role in
ISO-induced cardiac hypertrophy. The mRNA and protein expressions of BRD4 were increased in ISO-induced cardiac hypertrophy in vivo and in vitro (Figs. 1D, E, 2H and I). Inhibition or
knockdown of BRD4 prevented ISO-induced hypertrophic responses (Figs. 3, 5 and Fig. S3), whereas overexpression of BRD4
promoted the development of cardiomyocyte hypertrophy (Fig. 4).
These evidences indicate that BRD4 could be used as a biomarker
of cardiac hypertrophy. Future studies in hearts of Brd4/ mice
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Figure 9 The transcription elongation mediated by BRD4 is promoted by PARP1. (A) NRVMs were infected with Ad-PARP1 or treated with
ABT-888 after stimulation with ISO. (B)e(E) Chromatin immunoprecipitation (ChIP) was performed with a BRD4-specific antibody and qPCR
was conducted to determine the change of BRD4 abundance at ANP and BNP TSSs. (F) NRCMs were incubated with 3AB or ABT888
(10 mmol/L, 24 h) followed by Ad-PARP1 infection. The phosphorylation of RNA Pol II was determined by Western blot. Data are presented as
the mean  SEM, n Z 4; *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control or Ad-GFP group; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. ISO or AdPARP1 group.

will be conducted to provide a more solid support to our conclusions that BRD4 plays a pivotal role in cardiac hypertrophy.
The most intriguing finding of this study is that there exists
cross-interaction between BRD4 and PARP1. PARP1 is the most
abundant one among the 18 PARP isoforms, and accounts for
more than 90% of the catalytic activity of PARP44e46. Excessive
activation of PARP1 has been observed in the development of
various cardiovascular diseases, including atherosclerosis, acute
myocardial infarction/reperfusion injury and congestive heart
failure22,23. Indeed, this study shows that PARP1 activity was
increased in ISO-induced cardiac hypertrophy in vivo and in vitro
(Figs. 1G and 2K). Additionally, PARP1 overexpression induced
cardiomyocyte hypertrophy, while PARP1 inhibitors 3AB and
ABT-888 reversed ISO-induced upregulation of hypertrophic
genes (Fig. 6). These observations are consistent with previous
results in our laboratory24e26, suggesting that activation of PARP1
contributes to the development of cardiac hypertrophy. Interestingly, BRD4 is involved in PARP1-induced cardiac hypertrophy,
as implied by the observations that BRD4 inhibition or silencing
reversed PARP1-induced hypertrophic responses, and that BRD4
overexpression suppressed the anti-hypertrophic effect of PARP1
inhibitors (Fig. 8). These findings shed new lights on the mechanism of PARP1-induced cardiac hypertrophy via BRD4.
BRD4 has physical interaction with PARP1 and undergoes
PARylation by PARP1. This conclusion is supported by results of
IF, co-IP and PARylation assays (Fig. 7). The PARylation of
BRD4 was augmented by PARP1 overexpression, but was
reversed by PARP1 inhibitors, which was also restrained by

PARP1 knockdown in cardiomyocytes (Fig. 7D and E). In addition, the interaction of BRD4 and PAPR1, and PARylation of
BRD4, were enhanced when PARP1 activity was increased in
ISO-treated cardiomyocytes and heart tissues of SD rats, whereas
were alleviated by 3AB treatment (Fig. 7F and G). These results
suggest that PARylation of BRD4 is dependent on the activity of
PARP1, and that BRD4 is a substrate protein of PARP1. However,
the present study did not support that PARP1 PARylates the other
BET family members like BRD2, even though the mRNA levels
of Brd2 and Brd4 were both increased by ISO treatment (Fig. S2),
which implies that BRD2 might also participate in the development of cardiac hypertrophy. This conclusion is supported by the
co-IP results that PARP1 did not interact with BRD2 (Supporting
Information Fig. S6).
We further investigated the PARylation modification sites of
BRD4. During PARylation modification, ADP-riboses are transferred to the substrates. However, the number of transferred ADPriboses is hard to determine, which brings difficulties for identifying the modification sites. To determine the modification sites of
BRD4, we constructed three truncation mutants of BRD4 according to the domains of BRD4. BRD4 contains three kinds of
domains, including two tandem bromodomains (BD I and BD II),
an ET domain and a CTD region. The bromodomains are required
for epigenetic regulation of gene transcription through interaction
with nucleosomes within chromatin47. The ET domain is a
conserved region that fulfills its regulatory function by recruiting
specific effector proteins48. The CTD interacts with the positive
transcription elongation factor b (P-TEFb), a complex containing
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might suggest therapeutic potential for pathological cardiac
hypertrophy.
Acknowledgments

Figure 10 Scheme of this study. In response to hypertrophic
stimulus, BRD4 was PARylated by PARP1 which promoted the
recruitment of BRD4 at the TSS of hypertrophic genes, enhancing the
phosphorylation of RNA pol II, thereby promoting the transcription of
hypertrophic genes, ultimately inducing cardiac hypertrophy.

CDK9 and cyclin T, which is able to phosphorylates serine residues of the RNA Pol II C-terminal motif (CTM)49. Our data show
that P3 truncation of BRD4, which mainly contains CTD, was
PARylated by PARP1 (Fig. 7H). It thus suggests that the PARylation modification sites of BRD4 locate at CTD region. Since
PARylation usually takes place on Asp(D), Glu(E) and Lys(K),
and several PARylation motifs (PXE, EP, and EXXG) have been
identified50e52, six motifs within the CTD region are predicted to
be the potential PARylation sites (Supporting Information
Fig. S7). Future studies will be conducted to explore the exact
PARylation sites of BRD4 targeted by PARP1.
Taken into considerations that CTD region of BRD4 was
PARylated by PARP1, it is probable that the function of CTD in
BRD4 might be altered. The CTD of BRD4 is responsible for the
recruitment of PeTEFb complex to TSS of target genes. BRD4
promotes the activation of P-TEFb from its negative regulators
7SK RNA and HEXIM1 protein, facilitating Ser2 phosphorylation
in RNA Pol II, leading to the binding of Pol II to chromatin, finally
promoting transcription elongation53. Indeed, the binding of
BRD4 to TSS of hypertrophic genes and the phosphorylation of
RNA Pol II are promoted by BRD4 PARylation. This is implied
by the following observations: (1) PARP1 inhibition impaired the
binding of BRD4 to TSS of ANP and BNP; (2) PARP1 overexpression facilitated the recruitment of BRD4 to TSS of the
hypertrophic genes; and (3) the phosphorylation of RNA pol II
was enhanced by PARP1 overexpression, but was reversed by
BRD4 inhibitors (Fig. 9). It is still unclear how PARylation of
BRD4 facilitates its recruitment at TSS of hypertrophic biomarkers. It is speculated that PARylation of BRD4 might lead to a
change of its structure, and provides a stable structure conformation for the binding of PeTEFb complex and the hyperacetylated chromatin.

5.

Conclusions

The present study identifies PARylation as a novel posttranslational modification of BRD4 mediated by PARP1 that
participates in ISO-induced cardiac hypertrophy. PARylation of
BRD4 at the CTD domain facilitates its recruitment at
the TSS of hypertrophic genes, enhancing the phosphorylation
of RNA pol II, thereby promoting the transcription of hypertrophic genes, ultimately inducing cardiac hypertrophy
(Fig. 10). Strategies targeting inhibition of PARP1-BRD4
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